ICON Selected as Data Management Partner for UK Genomes Project
As data management partner, ICON will use its data management capabilities, and understanding of the growing role genomics data will have in clinical trials, to validate clinical data from the 70,000 participating patients and their families.
ICON announced that it has been selected by Genomics England as its data management partner for the 100,000 Genomes Project.
Announced by the British Prime Minister in 2012, the 100,0000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS) cancer and rare disease patients and their families. De-identified data from the Project will be made available to approved researchers from industry to help accelerate the development of new treatments and diagnostic tests that are targeted at the genetic characteristics of individual patients.
As Genomics England’s data management partner, ICON will use its data management capabilities, and understanding of the growing role genomics data will have in clinical trials, to validate clinical data from the 70,000 participating patients and their families. This work will take place within the secure Genomics England data environment.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
